keyword
https://read.qxmd.com/read/38619971/repression-of-yeats2-induces-cellular-senescence-in-hepatocellular-carcinoma-and-inhibits-tumor-growth
#1
JOURNAL ARTICLE
Qi Wu, Quan Zheng, Lei Yuan, Dandan Gao, Yabing Hu, Xinqing Jiang, Qiaocheng Zhai, Ming Liu, Lifeng Xu, Heng Xu, Jinlin Ye, Feng Zhang
Hepatocellular carcinoma (HCC) stands as the third leading cause of cancer-related fatalities globally. In this study, we observed a significant increase in the expression level of the YEATS2 gene in HCC patients, and it is negatively correlated with the patients' survival rate. While we have previously identified the association between YEATS2 and the survival of pancreatic cancer cells, the regulatory mechanisms and significance in HCC are still to be fully elucidated. Our study shows that knockdown (KD) of YEATS2 expression leads to DNA damage, which in turn results in an upregulation of γ-H2A...
April 15, 2024: Cell Cycle
https://read.qxmd.com/read/38598844/impact-of-surgery-induced-myeloid-derived-suppressor-cells-and-the-nox2-ros-axis-on-post-operative-survival-in-human-pancreatic-cancer
#2
JOURNAL ARTICLE
Hanna Grauers Wiktorin, Ebru Aydin, Roberta Kiffin, Caroline Vilhav, Johan Bourghardt Fagman, Mustafa Kaya, Sanchari Paul, Beatrice Westman, Svein Olav Bratlie, Peter Naredi, Kristoffer Hellstrand, Anna Martner
Preclinical studies imply that surgery triggers inflammation that may entail tumor outgrowth and metastasis. The potential impact of surgery-induced inflammation in human pancreatic cancer is insufficiently explored. This study included 17 patients with periampullary cancer (pancreatic ductal adenocarcinoma (PDAC) n=14, ampullary carcinoma n=2, cholangiocarcinoma n=1) undergoing major pancreatic cancer surgery with curative intent. We analyzed the potential impact of pre- and postoperative immune phenotypes and function on postoperative survival with >30 months follow-up...
April 10, 2024: Cancer Res Commun
https://read.qxmd.com/read/38596297/empowering-pancreatic-tumor-homing-with-augmented-anti-tumor-potency-of-cxcr2-tethered-car-nk-cells
#3
JOURNAL ARTICLE
Jong Hyeon Yoon, Han-Na Yoon, Hyun Ju Kang, Hyejin Yoo, Moon Jung Choi, Joo-Yoon Chung, Minkoo Seo, Minsung Kim, Si On Lim, Yong Jun Kim, Jin-Ku Lee, Mihue Jang
Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells are a promising immunotherapy for solid cancers; however, their effectiveness against pancreatic cancer is limited by the immunosuppressive tumor microenvironment. In particular, low NK cell infiltration poses a major obstacle that reduces cytotoxicity. The current study aimed to enhance the tumor-homing capacity of CAR-NK cells by targeting the chemokine-chemokine receptor axis between NK and pancreatic cancer cells. To this end, data from a chemokine array and The Cancer Genome Atlas pan-cancer cohort were analyzed...
March 21, 2024: Mol Ther Oncol
https://read.qxmd.com/read/38554155/il-2-promotes-expansion-and-intratumoral-accumulation-of-tumor-infiltrating-dendritic-cells-in-pancreatic-cancer
#4
JOURNAL ARTICLE
Tingting Gong, Xinyang Huang, Zhuoxin Wang, Ye Chu, Lifu Wang, Qi Wang
This study aims to investigate the diagnostic potential of IL-2 for PDAC and develop a method to improve the dendritic cell (DC) based vaccine against PDAC. The gene expression data and clinical characteristics information for 178 patients with PDAC were obtained from The Cancer Genome Atlas (TCGA). DCs were isolated from Human peripheral blood mononuclear cells (PBMCs) and were cultured in 4 different conditions. DCs were pulsed by tumor cell lysates or KRAS G12D1 - 23 peptide, and then used to activate T cells...
March 30, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38510243/high-hypoxia-status-in-pancreatic-cancer-is-associated-with-multiple-hallmarks-of-an-immunosuppressive-tumor-microenvironment
#5
JOURNAL ARTICLE
Hassan Sadozai, Animesh Acharjee, Hateem Z Kayani, Thomas Gruber, Reginald M Gorczynski, Bernard Burke
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is a particularly lethal disease that is often diagnosed late and is refractory to most forms of treatment. Tumour hypoxia is a key hallmark of PDAC and is purported to contribute to multiple facets of disease progression such as treatment resistance, increased invasiveness, metabolic reprogramming, and immunosuppression. METHODS: We used the Buffa gene signature as a hypoxia score to profile transcriptomics datasets from PDAC cases...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38501838/combining-bulk-and-scrna-seq-to-explore-the-molecular-mechanisms-governing-the-distinct-efferocytosis-activities-of-a-macrophage-subpopulation-in-pdac
#6
JOURNAL ARTICLE
Shaoliang Zhu, Quan Cheng, Mengjie Zou, Chunxing Li, Yi Tang, Longjie Xia, Yanming Jiang, Zheng Gong, Zhenyong Tang, Yuntian Tang, Honglin Luo, Ningfu Peng, Xiaojing Wang, Xiaofeng Dong
Pancreatic ductal adenocarcinoma (PDAC), a very aggressive tumour, is currently the third leading cause of cancer-related deaths. Unfortunately, many patients face the issue of inoperability at the diagnostic phase leading to a quite dismal prognosis. The onset of metastatic processes has a crucial role in the elevated mortality rates linked to PDAC. Individuals with metastatic advances receive only palliative therapy and have a grim prognosis. It is essential to carefully analyse the intricacies of the metastatic process to enhance the prognosis for individuals with PDAC...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38471639/knocking-down-of-xkr8-enhances-chemotherapy-efficacy-through-modulating-tumor-immune-microenvironment
#7
JOURNAL ARTICLE
Yuang Chen, Chien-Yu Chen, Haozhe Huang, Zhangyi Luo, Yiqing Mu, Shichen Li, Song Li
Scramblase Xkr8 regulates the externalization of phosphatidylserine (PS) during apoptosis and holds a pivotal role in fostering tumor immunosuppression. Targeting Xkr8 in conjunction with chemotherapy demonstrated a novel avenue for amplifying antitumor immune response and overcoming chemo-immune resistance. Here we further evaluated this strategy by using a clinically relevant orthotopic model and elucidated the mechanism through in-depth single-cell RNA sequencing (scRNA-seq). We found that Xkr8 knockdown exhibited the potential to lead to immunogenic cell death (ICD) by impeding the normal clearance of apoptotic cells...
March 10, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38377170/programmed-remodeling-of-the-tumor-milieu-to-enhance-nk-cell-immunotherapy-combined-with-chemotherapy-for-pancreatic-cancer
#8
JOURNAL ARTICLE
Xiaohu Yang, Chunyan Li, Hongchao Yang, Tuanwei Li, Sisi Ling, Yejun Zhang, Feng Wu, Xiaoguo Liu, Shaoqin Liu, Chunhai Fan, Qiangbin Wang
Natural killer (NK) cell-based adoptive immunotherapy has demonstrated encouraging therapeutic effects in clinical trials for hematological cancers. However, the effectiveness of treatment for solid tumors remains a challenge due to insufficient recruitment and infiltration of NK cells into tumor tissues. Herein, a programmed nanoremodeler (DAS@P/H/pp) is designed to remodel dense physical stromal barriers and for dysregulation of the chemokine of the tumor environment to enhance the recruitment and infiltration of NK cells in tumors...
February 20, 2024: Nano Letters
https://read.qxmd.com/read/38339310/the-role-of-chemokines-in-orchestrating-the-immune-response-to-pancreatic-ductal-adenocarcinoma
#9
REVIEW
Alexander A Lekan, Louis M Weiner
Chemokines are small molecules that function as chemotactic factors which regulate the migration, infiltration, and accumulation of immune cells. Here, we comprehensively assess the structural and functional role of chemokines, examine the effects of chemokines that are present in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME), specifically those produced by cancer cells and stromal components, and evaluate their impact on immune cell trafficking, both in promoting and suppressing anti-tumor responses...
January 28, 2024: Cancers
https://read.qxmd.com/read/38332843/combining-cisplatin-and-a-sting-agonist-into-one-molecule-for-metalloimmunotherapy-of-cancer
#10
JOURNAL ARTICLE
Shuren Zhang, Dongfan Song, Wenhao Yu, Ji Li, Xiaoyu Wang, Yachao Li, Zihan Zhao, Qi Xue, Jing Zhao, Jie P Li, Zijian Guo
Mounting evidence suggests that strategies combining DNA-damaging agents and stimulator of interferon genes (STING) agonists are promising cancer therapeutic regimens because they can amplify STING activation and remodel the immunosuppressive tumor microenvironment. However, a single molecular entity comprising both agents has not yet been developed. Herein, we designed two PtIV -MSA-2 conjugates ( I and II ) containing the DNA-damaging chemotherapeutic drug cisplatin and the innate immune-activating STING agonist MSA-2; these conjugates showed great potential as multispecific small-molecule drugs against pancreatic cancer...
January 2024: National Science Review
https://read.qxmd.com/read/38331849/il-15-secreting-car-natural-killer-cells-directed-toward-the-pan-cancer-target-cd70-eliminate-both-cancer-cells-and-cancer-associated-fibroblasts
#11
JOURNAL ARTICLE
Astrid Van den Eynde, Laura Gehrcken, Tias Verhezen, Ho Wa Lau, Christophe Hermans, Hilde Lambrechts, Tal Flieswasser, Delphine Quatannens, Gils Roex, Karen Zwaenepoel, Elly Marcq, Philippe Joye, Edgar Cardenas De La Hoz, Christophe Deben, Alessia Gasparini, Pierre Montay-Gruel, Maxim Le Compte, Eva Lion, Filip Lardon, Steven Van Laere, Vasiliki Siozopoulou, Diana Campillo-Davo, Jorrit De Waele, Patrick Pauwels, Julie Jacobs, Evelien Smits, Jonas R M Van Audenaerde
BACKGROUND: It remains challenging to obtain positive outcomes with chimeric antigen receptor (CAR)-engineered cell therapies in solid malignancies, like colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). A major obstacle is the lack of targetable surface antigens that are not shared by healthy tissues. CD70 emerges as interesting target, due to its stringent expression pattern in healthy tissue and its apparent role in tumor progression in a considerable amount of malignancies...
February 9, 2024: Journal of Hematology & Oncology
https://read.qxmd.com/read/38322253/an-fc-modified-monoclonal-antibody-as-novel-treatment-option-for-pancreatic-cancer
#12
JOURNAL ARTICLE
Martina S Lutz, Kevin Wang, Gundram Jung, Helmut R Salih, Ilona Hagelstein
Pancreatic cancer is a highly lethal disease with limited treatment options. Hence, there is a considerable medical need for novel treatment strategies. Monoclonal antibodies (mAbs) have significantly improved cancer therapy, primarily due to their ability to stimulate antibody-dependent cellular cytotoxicity (ADCC), which plays a crucial role in their therapeutic efficacy. As a result, significant effort has been focused on improving this critical function by engineering mAbs with Fc regions that have increased affinity for the Fc receptor CD16 expressed on natural killer (NK) cells, the major cell population that mediates ADCC in humans...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38266456/kif20b-and-met-hub-genes-of-diaphs-predict-poor-prognosis-and-promote-pancreatic-cancer-progression
#13
JOURNAL ARTICLE
Zhangqi Cao, Mingwei Guan, Chienshan Cheng, Fengjiao Wang, Yanhua Jing, Ke Zhang, Juying Jiao, Linjie Ruan, Zhen Chen
BACKGROUND: The DIAPHs (DIAPH1, DIAPH2, and DIAPH3) are members of the diaphanous subfamily of the formin family. KIF20B and MET, hub genes of DIAPHs, play crucial roles in cytoskeletal remodeling, cell migration, and adhesion. However, their combined prognostic and treatment value in pancreatic adenocarcinoma (PC) warrants further investigation. METHODS: Multiomics analysis tools were used to comprehensively assess the genomic expression and prognostic value of KIF20B and MET in PC...
December 21, 2023: Pathology, Research and Practice
https://read.qxmd.com/read/38244773/the-power-and-the-promise-of-car-mediated-cell-immunotherapy-for-clinical-application-in-pancreatic-cancer
#14
REVIEW
Hao-Yu Tang, Yi-Zhi Cao, Yi-Wei Zhou, Yu-Shui Ma, Hong Jiang, Hui Zhang, Lin Jiang, Qin-Xin Yang, Xiao-Mei Tang, Chun Yang, Xin-Yun Liu, Fu-Xing Liu, Ji-Bin Liu, Da Fu, Yun-Feng Wang, Hong Yu
BACKGROUND: Pancreatic cancer, referred to as the "monarch of malignancies," is a neoplastic growth mostly arising from the epithelial cells of the pancreatic duct and acinar cells. This particular neoplasm has a highly unfavorable prognosis due to its marked malignancy, inconspicuous initial manifestation, challenging early detection, rapid advancement, and limited survival duration. Cellular immunotherapy is the ex vivo culture and expansion of immune effector cells, granting them the capacity to selectively target malignant cells using specialized techniques...
January 18, 2024: Journal of Advanced Research
https://read.qxmd.com/read/38201305/chimeric-antigen-receptor-t-cell-therapy-for-pancreatic-cancer-a-review-of-current-evidence
#15
REVIEW
Agata Czaplicka, Mieszko Lachota, Leszek Pączek, Radosław Zagożdżon, Beata Kaleta
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of malignant and non-malignant disorders. CARs are synthetic transmembrane receptors expressed on genetically modified immune effector cells, including T cells, natural killer (NK) cells, or macrophages, which are able to recognize specific surface antigens on target cells and eliminate them. CAR-modified immune cells mediate cytotoxic antitumor effects via numerous mechanisms, including the perforin and granzyme pathway, Fas and Fas Ligand (FasL) pathway, and cytokine secretion...
January 4, 2024: Cells
https://read.qxmd.com/read/38196111/characterization-of-natural-killer-and-cytotoxic-t-cell-immune-infiltrates-in-pancreatic-ductal-adenocarcinoma
#16
JOURNAL ARTICLE
Julia Persky, Sylvia M Cruz, Morgan A Darrow, Sean J Judge, Yueju Li, Richard J Bold, Anthony N Karnezis, Karen E Matsukuma, Lihong Qi, Robert J Canter
BACKGROUND AND OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor response to systemic therapies, including immunotherapy. Given the immunotherapeutic potential of natural killer (NK) cells, we evaluated intratumoral NK cell infiltrates along with cytotoxic T cells in PDAC to determine their association with patient outcomes. METHODS: We analyzed tumors from 93 PDAC patients treated from 2012 to 2020. Predictor variables included tumor-infiltrating lymphocytes (TILs), T-cell markers (CD3, CD8, CD45RO), NK marker (NKp46), and NK inhibitory marker (major histocompatibility complex class I [MHC-I]) by immunohistochemistry...
January 9, 2024: Journal of Surgical Oncology
https://read.qxmd.com/read/38161257/surface-engineering-of-natural-killer-cells-with-cd44-targeting-ligands-for-augmented-cancer-immunotherapy
#17
JOURNAL ARTICLE
Sungjun Kim, Shujin Li, Ashok Kumar Jangid, Hee Won Park, Dong-Joon Lee, Han-Sung Jung, Kyobum Kim
Adoptive immunotherapy utilizing natural killer (NK) cells has demonstrated remarkable efficacy in treating hematologic malignancies. However, its clinical intervention for solid tumors is hindered by the limited expression of tumor-specific antigens. Herein, lipid-PEG conjugated hyaluronic acid (HA) materials (HA-PEG-Lipid) for the simple ex-vivo surface coating of NK cells is developed for 1) lipid-mediated cellular membrane anchoring via hydrophobic interaction and thereby 2) sufficient presentation of the CD44 ligand (i...
December 31, 2023: Small
https://read.qxmd.com/read/38159361/dual-crosslinking-immunostimulatory-hydrogel-synchronously-suppresses-pancreatic-fistula-and-pancreatic-cancer-relapse-post-resection
#18
JOURNAL ARTICLE
Ruizhi Zhao, Qiuqun Xiao, Yuanyuan Wu, Weiqi Zhang, Jiale Liu, Yinghua Zeng, Jie Zhan, Yanbin Cai, Chihua Fang
In pancreatic cancer (PC), surgical resection remains the sole curative option, albeit patients undergoing resection are susceptible to postoperative pancreatic fistula (PF) formation and tumor recurrence. An unmet need exists for a unified strategy capable of concomitantly averting PF and tumor relapse to mitigate morbidity in PC patients after surgery. Herein, an original dual crosslinked biological sealant hydrogel (methacrylate-hyaluronic acid-dopamine (MA-HA-DA) and sulfhydryl-hyaluronic acid-dopamine (SH-HA-DA)) was engineered as a drug depot and loaded with polydopamine-cloaked cytokine interleukin-15 and platelets conjugated with anti-TIGIT...
December 24, 2023: Biomaterials
https://read.qxmd.com/read/38106775/aggressive-biology-of-extra-nodal-nk-t-cell-lymphoma-a-case-report
#19
Chanh Huynh, Aman S Sandhu, Matthew Georgy, Rahul Kashyap
Extra-nodal NK/T cell lymphoma, nasal type (ENKTL) is a rare and aggressive non-Hodgkin lymphoma primarily seen in Asian and South American populations. Diagnosis involves methods like biopsy and molecular testing, with treatment typically combining systemic and radiation therapy. We present the rare case of a 62-year-old female who was diagnosed with localized ENKTL upon initial presentation of nasal congestion. She was started on radiation therapy and responded favorably at first, with decreased congestion and facial swelling...
November 2023: Curēus
https://read.qxmd.com/read/38102684/the-inter-link-of-ageing-cancer-and-immunity-findings-from-real-world-retrospective-study
#20
JOURNAL ARTICLE
Xiaomin Fu, Peng Qin, Fanghui Li, Huifang Zhu, Hongqin You, Yong Zhang, Benling Xu, Tiepeng Li, Fang Zhang, Lu Han, Lingdi Zhao, Baozhen Ma, Zibing Wang, Quanli Gao
BACKGROUND: Although the concept of declined immune function associated with cancer has been accepted extensively, real-world clinical studies focusing on analysis of the peripheral blood immune changes underlying ageing, immunity and cancer are scarce. METHODS: In this case-control study, we retrospectively analysed 1375 cancer patients and enrolled 275 age and gender matched healthy individuals. Flow cytometry was conducted to assess the immune changes. Further analysis was examined by SPSS 17...
December 15, 2023: Immunity & Ageing: I & A
keyword
keyword
57749
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.